Following approval by the European Commission in July, last week Accord Healthcare announced the launch of Zercepac® a biosimilar to Herceptin® in the United Kingdom.  According to the press release, Zercepac® is indicated for the treatment of certain patients with HER2-positive early breast cancer, HER2-positive metastatic breast cancer, and previously untreated HER2-positive metastatic gastric cancer.  Zercepac® will be available to patients in the UK in a 150 mg single-dose vials.